Shares of Mesoblast Limited MESO have soared 80% in one month following the FDA approval of remestemcel-L as the only ...

Mesoblast's FDA approval for remestemcel marks a milestone for MSC therapies, but limited cash reserves pose risks for US ...

Mesoblast Limited (NASDAQ:MESO – Get Free Report)’s share price hit a new 52-week high on Monday . The stock traded as high ...

Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...

Investors are sending the Mesoblast share price tumbling on Friday. But why? The post Why the Mesoblast share price is diving ...

The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...

Investors in biopharmaceutical company Mesoblast (MESO) are celebrating today as its shares are rocketing higher. The stock is trading for $21.09 as of this writing, marking a new 52-week high for ...

Mesoblast has gained US Food and Drug Administration (FDA) approval for its mesenchymal stromal cell (MSC) therapy, Ryoncil ...

Mesoblast Limited (AU:MSB) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street ...

The American depositary receipts of Mesoblast were trading higher after hours Wednesday following news the company will be added to the Nasdaq Biotechnology Index, effective Dec. 23. After the bell, ...

Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company’s proprietary manufacturing ...

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its upcoming ...